| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
Medicine details |
|
| Medicine name | upadacitinib (Rinvoq®) |
| Formulation | 15 mg and 30 mg prolonged release tablets |
| Reference number | 4224 |
| Indication | Treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy |
| Company | Abbvie Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/11/2021 |
| NICE guidance | TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |